- £198.21bn
- £217.54bn
- $54.07bn
- 85
- 16
- 86
- 71
REG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - AstraZeneca agrees to divest Viela shareholding
AnnouncementREG - AstraZeneca PLC - COVID-19 vaccine authorised for use by the EU
AnnouncementREG - AstraZeneca PLC - COVID-19 vaccine receives positive opinion in EU
AnnouncementREG - AstraZeneca PLC - Block listing application
AnnouncementREG - AstraZeneca PLC - Symbicort approved in China for mild asthma
AnnouncementREG - AstraZeneca PLC - Calquence approved in Japan for CLL
AnnouncementREG - AstraZeneca PLC - Calquence met primary endpoint against ibrutinib
AnnouncementREG - AstraZeneca PLC - Enhertu approved in the EU for breast cancer
AnnouncementREG - AstraZeneca PLC - Enhertu approved in the US for gastric cancer
AnnouncementREG - Jupiter Asset Mgmnt - Portfolio Update
AnnouncementREG - AstraZeneca PLC - Imfinzi new dosing approved in EU
AnnouncementREG - AstraZeneca PLC - Farxiga granted US Priority Review for CKD
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Atacand divestment in over 70 countries completed
AnnouncementREG - AstraZeneca PLC - AstraZeneca’s COVID-19 vaccine authorised in UK
AnnouncementREG - AstraZeneca PLC - Lynparza approved in Japan for three cancers
AnnouncementREG - AstraZeneca PLC - Tagrisso approved in the US for early lung cancer
AnnouncementREG - AstraZeneca PLC - Update on US regulatory review of roxadustat
Announcement